Health Pro Brief

Tue 5 November 2024 | View online

Hello

Commissioner-designate for Health, Oliver Várhelyi is causing concern among MEPs, talks are taking place to consider whether his role and responsibilities could me more circumscribed.

Negotiations are underway again on a pandemic agreement/accord/treaty/instrument. What it will finally be called is the least of its problems, with a US election looming large, we may be looking at an administration that is anti-vaccination and sceptical about international cooperation in general.

Today’s news

🟡 Commissioner-designate hearings

MEPs consider all options for Várhelyi

Rejection of Oliver Várhelyi, support, or reduction of his portfolio: EPP, S&D, and Renew Europe are trying to agree on a strategy ahead of the hearing for the potential future commissioner.


The future of Olivér Várhelyi as the Commissioner in charge of health is likely to be decided by a narrow margin. Leaders of the EPP, Renew Europe, and S&D groups met on Monday, 4 November, to review the different options available to them: supporting the candidate, rejecting him, or redefining his portfolio.


On the EPP side, although some internal divisions remain, they are leaning towards supporting the commissioner-designate from Hungary, while the S&D is pushing for a rejection of the candidate presented by Viktor Orbán.


In the Renew Europe group, there is hesitation between rejecting the candidate and reducing the scope of the portfolio. The idea suggested by some sources to Euractiv is to remove health from his responsibilities and leave him with animal welfare.


“It’s a bit complicated to let this figure through. Both rejection and a reduced portfolio are on the table,” a source told Euractiv.


Renew Europe MEPs held a closed-door meeting on Monday to try to make progress on the matter before it was raised at the top level with group leaders.


Olivér Várhelyi’s hearing will take place on 6 November and his evaluation will occur immediately afterward. “This means that the political groups’ strategies must be finalised before then,” another source informed Euractiv.


The candidate, nominated by Budapest, could be confirmed by MEPs following the hearing if a two-thirds majority is reached.


“It’s entirely possible. These hearings are often decided by just one or two votes,” a source told Euractiv.


If the candidate is rejected, he may be asked to appear for another hearing, requiring a majority vote. During this time, European Commission President Ursula von der Leyen could propose a reduced portfolio for Olivér Várhelyi. [CBB and TM]

Back to the top

🟡 United States elections

How would a Trump v Harris presidency affect health policy?

Global health: The Harris administration is set to take a similar approach to global health as President Joe Biden.


Overall, global health spending increased under Biden. In 2022, the US was the largest donor to global health, providing $15.8 billion dollars in health Official Development Assistance (ODA), although high spending was mostly driven by the COVID-19 pandemic.  


Harris will likely contribute to the World Health Organization’s (WHO) pandemic treaty negotiations. However, the Senate may resist any agreement made (expected May 2025 at the latest) as conservative commentators such as The Heritage Foundation have said the treaty threatens American national sovereignty. This claim has been described as “an outright lie by” Director-General of the World Health Organization Dr Tedros Adhanom Ghebreyesus (see yesterday’s Health Pro Brief), the current text of the agreement explicitly rules this out.


Biden has not been without critics in the field of health. In 2024, he cut funding for the President’s Emergency Plan for AIDS Relief which has been credited with saving 25 million lives in Africa, citing budgetary concerns.


Pharmaceuticals: Bolstering investment in pharmaceuticals and R&D, much like the Biden administration, is central to Harris' economic plans.  


Like the EU, the US has struggled to address medicine shortages and has a similar dependence on Chinese and Indian active pharmaceutical ingredients (APIs, or raw materials).


Harris has stated that she wants to cut drug prices through a new insurance plan in the Affordable Care Act and take on Big Pharma by broadening the number of drugs eligible for Medicare price negotiations.  This process has started, with the first drugs named.


In 2022, the Biden-Harris administration passed national legislation to lower drug prices for seniors as part of the Inflation Reduction Act.  


If Harris is elected and keeps her promise to hold ‘Big Pharma’ accountable, this may inspire EU member states to do the same – even if prices can vary by 240 percent for prescription brand-name drugs on the opposite side of the Atlantic.  


Reproductive health : Under the Biden administration, the president promised to restore Roe and blamed Trump for the overturning of Roe v Wade, a landmark Supreme Court judgement which made abortion a constitutional right in the US.


Harris has put the issue of reproductive rights and abortion in the spotlight, in sharp contrast to former President Donald Trump. However, if elected it is unlikely that she can restore and codify Roe, the only way to circumvent the court’s decision, as it is expected that she will be blocked by a divided House and Senate. [EP]


And Trump?


‘Concept’ of a plan: We don’t know much about what Trump’s actual healthcare policy is, but he has declared that he has the “concepts of a plan”. Primarily, he has said that he wants to replace the Affordable Care Act, the totemic achievement of the Obama administration. Nevertheless, with his usual braggadocio he has promised that his plan will be cheaper and better. What’s not to like!


He’s said that he can pretty much end all wars, including the one in Ukraine overnight, so if this is possible then maybe… We will trust our readers' judgement.


Don’t mention the pandemic: What the Democrats have not made much of is Trump’s record during the Covid-19 pandemic. The Trump administrations to underplay the threat and the ‘slow and mismanaged’ response is estimated to have cost thousands of lives.  


But lessons have been learnt, right? Trump has been endorsed by the promoter of vaccine conspiracy theories Robert F. Kennedy junior. Trump has said that he is open to banning vaccines, while on the campaign trail and promised him ‘control of the public health agencies’. [CF]

Back to the top

🟡 Pandemic agreement

WHO member states weigh in on pandemic agreement during opening session

The Intergovernmental Negotiating Body (INB) recommenced their negotiations on a pandemic agreement this morning (4 November).


In the opening session, with an eye on recent COVID, Marburg and mpox outbreaks, World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus said that a pandemic treaty without Pandemic Prevention, Preparedness and Response (PPPR) was “not a pandemic agreement at all.”  


Despite the COVID pandemic which resulted in over 20 million deaths, negotiations last year slowed down amid political disagreements. It is now expected to be agreed by May 2025 at the latest, three years after it was initially begun.  


A point of contention: Negotiations are expected to be tense around the Pathogen Access and Benefit-Sharing (PABS), a system built to ensure that member states have timely access to pathogens with pandemic potential. Members from the Global South noted it should be balanced with equitable sharing of benefits; Burkina Faso and Nambia said it was the “heartbeat of the agreement.”


December deadline unlikely? Several members said it would be useless to rush for a December pandemic agreement deadline if the details were not agreed on, with Eswatini saying it would not be “worth the paper it was written on,” if it were to go through while omitting key issues such as technology transfer, equity and sustainable financing.  


Key issues remain: An analysis by the Coalition of Advocates for Global Health and Pandemic Preparedness scored the Pandemic Accord on several of its articles last Thursday (31 October).


They said that civil society organisations and communities were not meaningfully engaged during negotiations, PPPR financing was not explicit and a commitment to technology transfer was not present in the draft agreement, among other issues.  [EP]

Back to the top

🟡 In the capitals

Supported by Efpia

UK declares two further cases of mpox Clade 1b

UK - Following the announcement last week of the first case of mpox detected in the UK,  the Health Security Agency (UKSHA) has confirmed two further cases.


The cases share a household with the first case. The patients are currently being treated in Guy’s and St Thomas’ NHS Foundation Trust in London.


“Mpox is very infectious in households with close contact and so it is not unexpected to see further cases within the same household,” said Professor Susan Hopkins, Chief Medical Adviser at UKHSA.


She added that the overall risk to the UK population remained low, “We are working with partners to make sure all contacts of the cases are identified and contacted to reduce the risk of further spread.”


Contact tracing with the patients is taking place. All contacts will be offered testing and vaccination. If a contact tests positive they will be advised on any further action and care needed. [CF]

Back to the top

Spanish government strengthens disease control surveillance following floods

Spain - Spanish Health Minister Mónica García announced yesterday (4 November) that the government is sending the Head of the Health Alerts and Emergencies Coordination Centre (CCAES), María José Sierra, to Valencia, along with a team of professionals who are coordinating on the ground with the Generalitat Valenciana to prevent outbreaks.


García says that the main challenge now is epidemiological surveillance and prevention of the outbreak of disease. The health ministry is updating protocols and instructions to intensify detection, sampling, identification and monitoring efforts.


García previously announced that the government had established five groups for the protection of public health: Early detection of diseases, especially infectious ones, related to the catastrophe; water quality control and determination of priority parameters in the affected area; evaluation of the need for specific vaccinations against vaccine-preventable diseases; risks and control measures related to vectors, with support from the ‘State Vector Plan Committee’; and expanded recommendations on food safety.


“We are not letting our guard down and are redoubling our efforts,” said García.[CF]

Back to the top

French MPs vote for amendments to make the ‘Nutri-Score’ mandatory

France - Members of the French National Assembly have voted to support two amendments to the Social Security Financing Bill (PLFSS) to make the display of the ‘Nutri-Score’ on foodstuffs mandatory.


The five-colour logo (with letters), rates foods from most (A, green) to least (E, red) healthy

are preventing its extension to the whole of Europe.


"Chronic diseases are increasing by 4% every year (...) That is why our [health] system is in danger," said Cyrille Isaac-Sibille (Les Démocrates), who put forward the two amendments. "The objective of our approach is not to ask the French to give up certain foods, but to inform them about the risks to their health and to encourage them to adapt their consumption accordingly.”


The amendments received support from La France insoumise (The Left) and other parties, but MPs from Rassemblement national (RN) and Droite républicaine, expressed concern that local products would be rated as D or E.


However, the amendments are very unlikely to be adopted. Minister of Health, Geneviève Darrieussecq said, “We will not make the Nutri-Score mandatory, we will follow the European directives."


Nevertheless, the minister expressed her support for its development at a European level.

Back to the top

🟡 Agenda

What’s coming up

Tuesday 5/11

Wednesday 6/11

Thursday 7/11

Friday 8/11

Monday 11/11

Read more

Today’s brief was brought to you by Euractiv’s Health team

Today’s briefing was prepared by the Health team: Catherine Feore, Clara Bauer-Babef, Emma Pirnay, Thomas Mangin, and Lydia Williams. Share your feedback or information with us at digital@euractiv.com.

Transfer to third parties is not authorised. If you found this newsletter valuable, please recommend a free trial.

Contact us - Manage your briefing subscriptions

© Euractiv. All rights reserved.